# Physical stimuli-responsive CRISPR-Cas9 systems for spatiotemporally precise control of genome engineering

**Authors:** Jinbin Pan, Bingjie Li, Yaqiong Wang, Yating Han, Guijun Liu, Shao-Kai Sun

PMC · DOI: 10.7150/thno.122238 · 2026-01-01

## TL;DR

This paper reviews how physical stimuli can control CRISPR-Cas9 to improve precise genome editing in specific cells or tissues.

## Contribution

The paper introduces physical stimuli-responsive CRISPR-Cas9 systems as a novel approach for spatiotemporal control of genome editing.

## Key findings

- Physical stimuli offer superior spatiotemporal precision and biocompatibility compared to chemical inducers.
- Current physical stimuli-responsive systems show improved controllability and target specificity.
- A comparative analysis highlights limitations and future directions for clinical translation.

## Abstract

The Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9 (CRISPR-Cas9) endonuclease system has revolutionized biology research by enabling precise, efficient, and versatile genome editing. However, achieving spatiotemporally controlled gene editing within specific organs, tissues, or cells remains a major challenge, as unregulated CRISPR-Cas9 activity can lead to severe off-target effects, hindering its clinical translation. To enhance the on-target precision and reduce the unwanted consequences of aberrant or premature CRISPR-Cas9 activation, various strategies have been developed to regulate its function at translational or post-translational stages using diverse external physicochemical stimuli. While chemical molecule-inducible CRISPR-Cas9 systems have demonstrated significant progress, most of them still suffer from inherent deficiencies, such as unsatisfactory spatiotemporal precision, irreversibility, pharmacokinetic dependence, internal disturbance, and safety concerns related to chemical inducers. By contrast, externally applied physical stimuli provide distinct advantages for triggering CRISPR-Cas9 activity, offering superior spatiotemporal precision, reversibility, and biocompatibility. These features significantly enhance the controllability, target specificity, and practical applicability of CRISPR-Cas9 systems across diverse biological settings. This review systematically explores recent advances in physical stimuli-responsive CRISPR-Cas9 platforms, detailing their design strategies, activation mechanisms, and proof-of-concept applications. Furthermore, we provide a comparative analysis of different stimulation strategies, highlighting their respective characteristics, current limitations, and future prospects. A discussion on the persistent bench-to-bedside gap is also included, aiming to guide future development toward clinically viable solutions.

## Full-text entities

- **Genes:** NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, CIB1 (calcium and integrin binding 1) [NCBI Gene 10519] {aka CIB, CIBP, EV3, KIP1, PRKDCIP, SIP2-28}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, PLK1 (polo like kinase 1) [NCBI Gene 5347] {aka PLK, STPK13}, RNPC3 (RNA binding region (RNP1, RRM) containing 3) [NCBI Gene 55599] {aka CPHD7, IGHD5, RBM40, RNP, SNRNP65}, PIEZO1 (piezo type mechanosensitive ion channel component 1 (Er blood group)) [NCBI Gene 9780] {aka DHS, ER, FAM38A, LMPH3, LMPHM6, Mib}, DHFR (dihydrofolate reductase) [NCBI Gene 1719] {aka DHFR1, DYR}, PSPN (persephin) [NCBI Gene 5623] {aka PSP}, CRY2 (cryptochrome circadian regulator 2) [NCBI Gene 1408] {aka HCRY2, PHLL2}, HSP90B2P (heat shock protein 90 beta family member 2, pseudogene) [NCBI Gene 7190] {aka GRP94P1, GRP94b, HSP, HSPCP2, TRA1P1, TRAP1}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, FASTK (Fas activated serine/threonine kinase) [NCBI Gene 10922] {aka FAST}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, MATN1 (matrilin 1) [NCBI Gene 4146] {aka CMP, CRTM}
- **Diseases:** alpha-1 antitrypsin deficiency (MESH:D019896), fulminant hepatic failure (MESH:D017114), cytotoxicity (MESH:D064420), cancer (MESH:D009369), Leber congenital amaurosis type 10 (MESH:C565720), brain diseases (MESH:D001927), melanoma (MESH:D008545), fibrosis (MESH:D005355), hypothermia (MESH:D007035), HSE (MESH:D012769), inflammation (MESH:D007249), hypoxia (MESH:D000860), hyperthermia (MESH:D005334), Duchenne muscular dystrophy (MESH:D020388), genetic diseases (MESH:D030342), hereditary tyrosinemia (MESH:D020176), androgenic alopecia (MESH:D000505), Phototoxicity (MESH:D017484)
- **Chemicals:** PC (MESH:C053518), carbon (MESH:D002244), polymer (MESH:D011108), phenanthrenequinone (MESH:C005399), PEI (MESH:D011094), vitamin E (MESH:D014810), LACP (MESH:C053078), N1-methyladenosine (MESH:C002230), thiol (MESH:D013438), TMP (MESH:D014295), verteporfin (MESH:D000077362), disulfide (MESH:D004220), PI (MESH:D010716), singlet oxygen (MESH:D026082), ABA (MESH:D000040), gold (MESH:D006046), Ca2+ (-), N6-methyladenosine (MESH:C010223), hyaluronic acid (MESH:D006820), lanthanide (MESH:D028581), ROS (MESH:D017382), calcium (MESH:D002118), heavy metal (MESH:D019216), Mxenes (MESH:C000723374), lysine (MESH:D008239), oligonucleotides (MESH:D009841), lipid (MESH:D008055), glutathione (MESH:D005978), azobenzene (MESH:C009850), m6A (MESH:C005955)
- **Species:** Homo sapiens (human, species) [taxon 9606], Lacticaseibacillus rhamnosus GG (strain) [taxon 568703], Mus musculus (house mouse, species) [taxon 10090], Danio rerio (leopard danio, species) [taxon 7955], Metazoa (animals, kingdom) [taxon 33208], Human immunodeficiency virus 1 (no rank) [taxon 11676], Streptococcus pyogenes (species) [taxon 1314]
- **Mutations:** V600E, D10A, H840A, A-to-I
- **Cell lines:** tsRC9 — Capra hircus (Goat), Conditionally immortalized cell line (CVCL_WK98), Cas13 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_A4EM), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), SpCas9 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_RG56)

## Figures

19 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12775815/full.md

---
Source: https://tomesphere.com/paper/PMC12775815